Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause
- 1 October 1990
- journal article
- research article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 33 (2), 149-152
- https://doi.org/10.1016/0020-7292(90)90588-c
Abstract
The value of using CA 125 for screening of ovarian carcinoma is still under debate. It is important to be aware of possible physiological variation in serum levels of this antigen. This study aimed at finding out whether there were any differences in CA 125 levels in serum at different cycle day periods of fertile women and postmenopausal women. In 106 women, CA 125 and ovarian volume were measured at different cycle day periods and in postmenopausal women. The highest levels were found in cycle day (CD) 1-9, i.e. 22 units/ml and the lowest in postmenopausal women i.e. 6.7 units/ml. No correlation could be found between the CA 125 levels and ovarian volume as measured by vaginal sonography.Keywords
This publication has 15 references indexed in Scilit:
- The CA 125 tumour-associated antigen: a review of the literatureHuman Reproduction, 1989
- MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCERThe Lancet, 1988
- A comparison between ultrasound and gynecologic examination for detection of enlarged ovaries in a group of women at risk for ovarian carcinoma.Journal of Ultrasound in Medicine, 1988
- CA 125 in serum, peritoneal fluid, active lesions, and endometrium of patients with endometriosisAmerican Journal of Obstetrics and Gynecology, 1988
- Comparison between endovaginal and transabdominal transducers for measuring ovarian volume.Journal of Ultrasound in Medicine, 1987
- Serum CA-125 antigen levels increase during mensesAmerican Journal of Obstetrics and Gynecology, 1987
- The use of CA-125 in the diagnosis and management of endometriosisFertility and Sterility, 1986
- Elevated serum concentrations of CA-125 in patients with advanced endometriosisFertility and Sterility, 1986
- Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigenAmerican Journal of Obstetrics and Gynecology, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983